BioCryst Pharmaceuticals Inc (BCRX)
8.43
+0.42
(+5.24%)
USD |
NASDAQ |
Nov 01, 16:00
8.50
+0.07
(+0.83%)
After-Hours: 20:00
BioCryst Pharmaceuticals Debt to Equity Ratio: -1.700 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | -1.700 |
| March 31, 2024 | -1.708 |
| December 31, 2023 | -1.781 |
| September 30, 2023 | -2.027 |
| June 30, 2023 | -2.108 |
| March 31, 2023 | -2.275 |
| December 31, 2022 | -2.489 |
| September 30, 2022 | -2.941 |
| June 30, 2022 | -0.6777 |
| March 31, 2022 | -3.681 |
| December 31, 2021 | -5.472 |
| September 30, 2021 | -1.102 |
| June 30, 2021 | -1.478 |
| March 31, 2021 | -2.041 |
| December 31, 2020 | -14.25 |
| September 30, 2020 | 2.257 |
| June 30, 2020 | 1.053 |
| March 31, 2020 | 21.99 |
| December 31, 2019 | 2.088 |
| September 30, 2019 | -1.928 |
| June 30, 2019 | -8.614 |
| March 31, 2019 | 3.503 |
| December 31, 2018 | 1.200 |
| September 30, 2018 | 0.8086 |
| June 30, 2018 | 1.059 |
| Date | Value |
|---|---|
| March 31, 2018 | 0.8122 |
| December 31, 2017 | 0.6195 |
| September 30, 2017 | 0.5135 |
| June 30, 2017 | 2.137 |
| March 31, 2017 | 1.330 |
| December 31, 2016 | 32.33 |
| September 30, 2016 | 12.72 |
| June 30, 2016 | 2.093 |
| March 31, 2016 | 1.004 |
| December 31, 2015 | 0.5826 |
| September 30, 2015 | 0.4684 |
| June 30, 2015 | 0.3943 |
| March 31, 2015 | 0.466 |
| December 31, 2014 | 0.3966 |
| September 30, 2014 | 0.3595 |
| June 30, 2014 | 0.333 |
| March 31, 2014 | -5.242 |
| December 31, 2013 | -26.64 |
| September 30, 2013 | 8.798 |
| June 30, 2013 | -3.316 |
| March 31, 2013 | -10.56 |
| December 31, 2012 | -66.08 |
| September 30, 2012 | 3.066 |
| June 30, 2012 | 1.916 |
| March 31, 2012 | 1.296 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-14.25
Minimum
Dec 2020
21.99
Maximum
Mar 2020
-0.9654
Average
-1.781
Median
Dec 2023
Debt to Equity Ratio Benchmarks
| Novavax Inc | -0.3911 |
| AIM ImmunoTech Inc | 0.4322 |
| Perspective Therapeutics Inc | -- |
| Protalix BioTherapeutics Inc | 0.7145 |
| Armata Pharmaceuticals Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 472.42M |
| Total Liabilities (Quarterly) | 948.02M |
| Shareholders Equity (Quarterly) | -475.61M |
| Current Ratio | 2.816 |
| Net Debt Paydown Yield | -0.96% |